IFP Advisors’s Agios Pharmaceuticals AGIO Stock Holding History

IFP Advisors’s Portfolio AGIO Stock Details AGIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$8.65K	Buy	233 +231	+11,550%	+$7.01K	﹤0.01%	3486
2026 Q1	$68	Sell	2 -4	-67%	-$113	﹤0.01%	4794
2025 Q4	$163	Hold	6	–	–	﹤0.01%	4509
2025 Q3	$241	Buy	+6	New	+$226	﹤0.01%	4358
2025 Q2	–	Hold	0	–	–	–	3928
2025 Q1	–	Sell	-3	Closed	-$99	–	4302
2024 Q4	$99	Buy	+3	New	+$141	﹤0.01%	4033
2021 Q4	–	Sell	-29	Closed	-$1K	–	3375
2021 Q3	$1K	Hold	29	–	–	﹤0.01%	2964
2021 Q2	$2K	Hold	29	–	–	﹤0.01%	2707
2021 Q1	$1K	Hold	29	–	–	﹤0.01%	2779
2020 Q4	$1K	Hold	29	–	–	﹤0.01%	2718
2020 Q3	$1K	Hold	29	–	–	﹤0.01%	2587
2020 Q2	$2K	Buy	+29	New	+$1.34K	﹤0.01%	2350
2019 Q4	–	Sell	-18	Closed	-$680	–	2823
2019 Q3	$1K	Buy	+18	New	+$745	﹤0.01%	2817
2018 Q3	–	Sell	-52	Closed	-$4K	–	3800
2018 Q2	$4K	Buy	+52	New	+$4.54K	﹤0.01%	3329
2016 Q3	–	Sell	-225	Closed	-$9K	–	3882
2016 Q2	$9K	Buy	+225	New	+$11.1K	﹤0.01%	2781
2016 Q1	–	Sell	-230	Closed	-$15K	–	2363
2015 Q4	$15K	Buy	+230	New	+$15.1K	﹤0.01%	2321

Other funds holding AGIO

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM

IFP Advisors's AGIO Position: Q2 2026 in Review

IFP Advisors increased its Agios Pharmaceuticals (AGIO) stake by 11,550% in Q2 2026, buying an estimated $7.01K and bringing the position to 233 shares worth $8.65K. The position accounts for ﹤0.01% of the portfolio, ranked #3486.

IFP Advisors first reported a position in AGIO in Q4 2015 and has held it in 15 quarters since. The position peaked at $15K in Q4 2015. 238 funds tracked by Wall St. Rank hold AGIO as of Q2 2026.

IFP Advisors held 233 shares of Agios Pharmaceuticals worth $8.65K as of Q2 2026.
IFP Advisors bought 231 Agios Pharmaceuticals shares in Q2 2026, an estimated $7.01K.
Agios Pharmaceuticals made up ﹤0.01% of IFP Advisors's portfolio in Q2 2026, its #3486 holding.
IFP Advisors first reported a position in Agios Pharmaceuticals in Q4 2015 and has held it in 15 quarters since.
IFP Advisors's Agios Pharmaceuticals position peaked at $15K in Q4 2015.
238 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q2 2026.

Based on IFP Advisors's 13F filing for Q2 2026, filed 20 Jul 2026.